search
Back to results

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients (VBI-S-02) (VBI-S-02)

Primary Purpose

Septic Shock, Sepsis, Hypovolemia

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
VBI-S
Sponsored by
Vivacelle Bio
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female at least 18 years of age. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml. Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market. Sequential Organ Failure Assessment (SOFA) score ≥ 5 and ≤ 11 with the maximum SOFA score of 24. Failure of standard therapy defined as no decrease in the SOFA score for 48 hours or a SOFA score > 11 on admission to the ICU. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria: Lactate > 2 mmol/L Fever > 38.3°C, or 101°F Hypothermia < 36°C core temperature (<96.8°F) Heart rate > 90 Tachypnea (respiratory rate ≥ 20/min) White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature forms) Elevated procalcitonin in serum (≥ 2ng/ml) Arterial hypoxemia (PaO2/FiO2 < 300) Creatinine increase > 0.5 mg/dL INR > 1.5 or aPTT > 60 seconds Exclusion Criteria: Patients with a ventricular assist device Acute coronary syndrome Pregnant Acute bronchospasm Acute Mesenteric ischemia Emergency major surgery Diagnosis of acute Hepatitis B or C Hematologic or coagulation disorders including thrombocytopenia (platelet count < 50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure White blood cell count of < 1000 mm3 Current participation or participation in another experimental or device study with the last 30 days before the start of this study. Patient may be included if on other drugs for COVID-19 Patients with a known allergy to soybeans or eggs Patient is hypervolemic as assessed by ultrasound Patient expected to expire within 12 hours

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    VBI-S

    Arm Description

    Treatment with VBI-S

    Outcomes

    Primary Outcome Measures

    Elevation in Average Mean Arterial Pressure
    The primary endpoint is defined as an elevation in average mean arterial pressure by at least 10 mmHg.
    Adverse Drug Reactions
    The number of patients with adverse drug reactions.

    Secondary Outcome Measures

    Mean Blood Pressure Increase
    The number of patients in whom mean blood pressure increased by at least 10 mmHg.
    Dose of Pressor Drugs
    The number of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg.
    Sequential Organ Failure Assessment (SOFA) Score
    Change in Sequential Organ Failure Assessment (SOFA) Score on a scale of 0 to 24 .
    Ratio of Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen
    Change in ratio of partial pressure of oxygen in arterial blood/Fraction of inspired oxygen (P/F ratio).
    Arterial Oxygen Saturation
    Change in arterial oxygen saturation.
    Partial Pressure of Oxygen
    Change in partial pressure of oxygen.
    Arterial Blood pH
    Change in arterial blood pH.
    Arterial Blood Base Excess
    Change in arterial blood base excess.
    Arterial Blood Carbon Dioxide
    Change in arterial blood carbon dioxide.

    Full Information

    First Posted
    September 14, 2023
    Last Updated
    October 19, 2023
    Sponsor
    Vivacelle Bio
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06072430
    Brief Title
    VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients (VBI-S-02)
    Acronym
    VBI-S-02
    Official Title
    VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 2023 (Anticipated)
    Primary Completion Date
    August 2024 (Anticipated)
    Study Completion Date
    October 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Vivacelle Bio

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
    Detailed Description
    PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia. STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock. Randomization and blinding: This is an open label study, randomization and blinding are not applicable to this study. All patients entering this study will be treated with VBI-S. Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Septic Shock, Sepsis, Hypovolemia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    34 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    VBI-S
    Arm Type
    Experimental
    Arm Description
    Treatment with VBI-S
    Intervention Type
    Drug
    Intervention Name(s)
    VBI-S
    Intervention Description
    VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
    Primary Outcome Measure Information:
    Title
    Elevation in Average Mean Arterial Pressure
    Description
    The primary endpoint is defined as an elevation in average mean arterial pressure by at least 10 mmHg.
    Time Frame
    10 months
    Title
    Adverse Drug Reactions
    Description
    The number of patients with adverse drug reactions.
    Time Frame
    10 months
    Secondary Outcome Measure Information:
    Title
    Mean Blood Pressure Increase
    Description
    The number of patients in whom mean blood pressure increased by at least 10 mmHg.
    Time Frame
    10 months
    Title
    Dose of Pressor Drugs
    Description
    The number of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg.
    Time Frame
    10 months
    Title
    Sequential Organ Failure Assessment (SOFA) Score
    Description
    Change in Sequential Organ Failure Assessment (SOFA) Score on a scale of 0 to 24 .
    Time Frame
    10 months
    Title
    Ratio of Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen
    Description
    Change in ratio of partial pressure of oxygen in arterial blood/Fraction of inspired oxygen (P/F ratio).
    Time Frame
    10 months
    Title
    Arterial Oxygen Saturation
    Description
    Change in arterial oxygen saturation.
    Time Frame
    10 months
    Title
    Partial Pressure of Oxygen
    Description
    Change in partial pressure of oxygen.
    Time Frame
    10 months
    Title
    Arterial Blood pH
    Description
    Change in arterial blood pH.
    Time Frame
    10 months
    Title
    Arterial Blood Base Excess
    Description
    Change in arterial blood base excess.
    Time Frame
    10 months
    Title
    Arterial Blood Carbon Dioxide
    Description
    Change in arterial blood carbon dioxide.
    Time Frame
    10 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female at least 18 years of age. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml. Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market. Sequential Organ Failure Assessment (SOFA) score ≥ 5 and ≤ 11 with the maximum SOFA score of 24. Failure of standard therapy defined as no decrease in the SOFA score for 48 hours or a SOFA score > 11 on admission to the ICU. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria: Lactate > 2 mmol/L Fever > 38.3°C, or 101°F Hypothermia < 36°C core temperature (<96.8°F) Heart rate > 90 Tachypnea (respiratory rate ≥ 20/min) White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature forms) Elevated procalcitonin in serum (≥ 2ng/ml) Arterial hypoxemia (PaO2/FiO2 < 300) Creatinine increase > 0.5 mg/dL INR > 1.5 or aPTT > 60 seconds Exclusion Criteria: Patients with a ventricular assist device Acute coronary syndrome Pregnant Acute bronchospasm Acute Mesenteric ischemia Emergency major surgery Diagnosis of acute Hepatitis B or C Hematologic or coagulation disorders including thrombocytopenia (platelet count < 50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure White blood cell count of < 1000 mm3 Current participation or participation in another experimental or device study with the last 30 days before the start of this study. Patient may be included if on other drugs for COVID-19 Patients with a known allergy to soybeans or eggs Patient is hypervolemic as assessed by ultrasound Patient expected to expire within 12 hours
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Cuthbert O Simpkins, MD, FACS
    Phone
    3187711294
    Email
    cuthbert@vivacellebio.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Cuthbert O Simpkins, MD, FACS
    Organizational Affiliation
    Vivacelle Bio
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients (VBI-S-02)

    We'll reach out to this number within 24 hrs